Actuate Therapeutics (ACTU) Earnings Date & Reports

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

ACTU is expected to report earnings to fall 16.00% to -20 cents per share on February 25

Actuate Therapeutics ACTU Stock Earnings Reports

Q4'25

Est.

$-0.21

Q3'25

Missed

by $0.07

Q2'25

Missed

by $0.11

The last earnings report on December 03 showed earnings per share of -25 cents, missing the estimate of -18 cents. With 57.95K shares outstanding, the current market capitalization sits at 152.48M.

View a ticker or compare two or three

Compare

ACTU

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ACTU showed earnings on December 03, 2025. You can read more about the earnings report here.

View AI-Driven Trading for ACTU

A.I. Advisor

published General Information

General Information

Industry Biotechnology

Profile

Fundamentals

Details